Back to search
FDAFDA · Food and drugs·Recall number Z-1913-2019

ADVIA Chemistry Creatine Kinase (CK_L) reagent, Product Code 10729780, UDI Number: 00630414008943 - Product Usage: The ADVIA® Chemistry Creatine Kinase (CK_L) assay is for in vitro diagnostic use in the quantitative determination of creatine kinase activity in human plasma (lithium heparin) or serum on ADVIA Chemistry XPT systems. The assay can be used to aid in the diagnosis and treatment of myocardial infarction and muscle diseases, such as Duchenne progressive muscular dystrophy.

Published July 10, 2019 · Recall initiated: May 3, 2019

Summary

FDA records medical device Class II recall Z-1913-2019, published July 10, 2019 and initiated May 3, 2019. Recalling firm: Siemens Healthcare Diagnostics, Inc.; Status: Terminated; Reported quantity: 3,386; Lot: Serial Numbers: 465336,465663,468449. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

A steady upward trend in blank (u) absorbance was observed

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Siemens Healthcare Diagnostics, Inc.
Distributor
Worldwide distribution.
Lot
Serial Numbers: 465336,465663,468449
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was ADVIA Chemistry Creatine Kinase (CK_L) reagent, Product Code 10729780, UDI Number: 00630414008943 - Product Usage: The ADVIA® Chemistry Creatine Kinase (CK_L) assay is for in vitro diagnostic use in the quantitative determination of creatine kinase activity in human plasma (lithium heparin) or serum on ADVIA Chemistry XPT systems. The assay can be used to aid in the diagnosis and treatment of myocardial infarction and muscle diseases, such as Duchenne progressive muscular dystrophy. recalled?

Yes. FDA published recall Z-1913-2019 on July 10, 2019. Reported hazard: A steady upward trend in blank (u) absorbance was observed

What should I do if I have this product?

Voluntary: Firm initiated · Letter